REFERENCES
- Hartmann O, Pinkerton C R, Philip T, et al. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol 1988; 6: 44–50, [PUBMED], [INFOTRIEVE]
- Kushner B H, LaQuaglia M P, Bonilla M A, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12: 2607–2613, [PUBMED], [INFOTRIEVE]
- Tada T, Takizawa T, Nakazato F, et al. Treatment of intracranial non-germinomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neuro-Oncol 1999; 44: 71–76, [CSA], [CROSSREF]
- Glover D J, Glick J H, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574–578, [PUBMED], [INFOTRIEVE]
- Mollman J E, Glover D J, Hogan W M, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–2195, [PUBMED], [INFOTRIEVE]
- Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2102–2112
- Rubin J S, Wadler S, Beitler J J, et al. Audiological findings in a phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol 1995; 109: 744–777, [PUBMED], [INFOTRIEVE]
- Ramnath N, LoRusso P, Simon M, et al. Phase II evaluation of cisplatin and WR-2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997; 20: 368–372, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rick O, Beyer J, Schwella N, et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 2001; 12: 1151–1155, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koukourakis M I. Amifostine in clinical oncology: current use and future applications. Anti-Cancer Drugs 2002; 13: 181–209, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cavaletti G, Cascinu S, Venturino P, et al. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res 1996; 16: 3149–3159, [PUBMED], [INFOTRIEVE], [CSA]
- Green D, Bensley D, Schein P. Preclinical evaluation of WR 1513127: an orally active chemotherapy protector. Cancer Res 1994; 54: 738–741, [PUBMED], [INFOTRIEVE]
- Budd G T, Lorenzi V, Ganapathi R, et al. Amifostine potential for clinically useful cytoprotection. Support Care Cancer 1994; 2: 380–384, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fouladi M, Stempak D, Gammon J, et al. Phase I trial of twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer 2001; 92: 914–923, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Souid A K, Fahey R C, Dubowy R L, et al. Determination of the cytoprotective agent WR-2721 (amifostine, ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol 1998; 42: 400–406, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Souid A K, Fahey R C, Dubowy R L, et al. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. Cancer Chemother Pharmacol 1999; 44: 498–504, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]